Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin Add-on vs Metformin Escalation in T2DM
NCT06863532Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change in glycated hemoglobin levels at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06863532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863532.